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Abstract: The thyroid gland has a special relationship with oxidative stress. On the one hand,
like all other tissues, it must defend itself against reactive oxygen species (ROS). On the other hand,
unlike most other tissues, it must also produce reactive oxygen species in order to synthesize its
hormones that contribute to the homeostasis of other tissues. The thyroid must therefore also
rely on antioxidant defense systems to maintain its own homeostasis in the face of continuous
self-exposure to ROS. One of the main endogenous antioxidant systems is the pathway centered
on the transcription factor Nuclear factor erythroid 2-related factor 2 (Nrf2) and its cytoplasmic
inhibitor Kelch-like ECH-associated protein 1 (Keap1). Over the last few years, multiple links
have emerged between the Keap1/Nrf2 pathway and thyroid physiology, as well as various thyroid
pathologies, including autoimmunity, goiter, hypothyroidism, hyperthyroidism, and cancer. In the
present mini-review, we summarize recent studies shedding new light into the roles of Keap1/Nrf2
signaling in the thyroid.
Keywords: thyroid; Nrf2 (nuclear factor erythroid 2-related factor 2); Keap1 (Kelch-like
ECH-associated protein 1); thyroglobulin; oxidative stress; goiter; antioxidant
1. Introduction and Overview
When the cellular amounts of reactive oxygen species (ROS) are retained within physiological
levels, ROS can function as signaling molecules that play key roles in cellular processes. In contrast,
when the amounts of ROS exceed physiological levels, they are considered potent DNA-, protein-,
and lipid-damaging agents that cells need to defend themselves against. Oxidative stress (OS) is
the imbalance that occurs when the concentration of ROS overcomes the cell’s ability to detoxify
them using its endogenous antioxidant systems [1]. OS can initiate and maintain cellular damage,
including genomic instability, and it has been incriminated as a causative or exacerbating factor in a
variety of pathological conditions. Disorders linked to OS can affect many tissues, especially those
that are in direct contact with the external environment (e.g., lung), generate high amounts of free
radicals as either mediators or side-products of their normal physiology (e.g., muscle), have roles in
detoxification (e.g., liver), or are, in general, especially sensitive to free radicals (e.g., neurons) [2].
Hydrogen peroxide (H2O2) is a relatively stable ROS that is important for many cellular functions,
including signaling, host defense, wound healing, cell death, etc. [3]. Physiological levels of H2O2
are especially important for the normal functioning and hormone-producing capacity of the thyroid
gland. The thyroid is an endocrine gland responsible primarily for the production of the thyroid
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hormones thyroxine (T4) and triiodothyronine (T3), which act on all cells in the body to regulate
development, growth, and metabolism. Synthesis of these hormones takes place in special spherical
structures called thyroid follicles, whose periphery is lined by thyroid follicular cells. Thyroid hormone
synthesis is a complex and multistep process that comprises a series of redox reactions that use H2O2
as the primary oxidative agent (Figure 1) [4]. Considering that the levels of H2O2, similar to those of
other ROS, should remain balanced in order to prevent OS, thyroid follicular cells also need to have a
potent antioxidant system, including a cellular sensor for oxidants and a mediator of the antioxidant
response. In our studies over the last few years, we have shown that the antioxidant signaling pathway
comprising the transcription factor Nrf2 (Nuclear factor erythroid 2-related factor 2) and its cytoplasmic
inhibitor Keap1 (Kelch-like ECH-associated protein 1) is a main system employed by the thyroid for its
antioxidant defense [5], similar to other tissues [6].
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Figure 1. Schematic simplified representation of thyroid hormone synthesis. Iodide (I−) enters thyroid 
follicular cells by active transport via the sodium (Na+)-iodide symporter (NIS), and is then exported 
via other channels into the follicular lumen (the colloid area), where it is oxidized to iodine (I) and 
used in the iodination of thyroglobulin (Tg). Coupling between di- and/or mono-iodinated tyrosines 
of Tg produces the thyroid hormones T4 and T3, attached to the Tg backbone. Tg is then endocytosed 
into the thyroid follicular cells, where it is degraded inside lysosomes, ultimately releasing T4 and T3 
into the blood circulation via a monocarboxylate transporter (MCT). Steps affected by Keap1/Nrf2 
signaling are highlighted in red font. They include: (i) a positive effect on the transcription of the gene 
encoding Tg; (ii) a positive effect on the transcription of antioxidant and selenoprotein genes such as 
Nqo1 (NAD(P)H quinone dehydrogenase 1), Gpx2 (glutathione peroxidase 2), and Txnrd1 (thioredoxin 
reductase 1); a negative effect on Tg iodination; (iv) a positive effect on Tg proteolysis. 
Under normal conditions, Keap1 acts as an adaptor that targets Nrf2 for poly-ubiquitination by 
Cullin 3-based ubiquitin E3 ligase (Cul3) and subsequent degradation by the proteasome. The thiol 
groups on specific Keap1 cysteines react readily with oxidants, including H2O2, and their oxidation 
impairs the presentation of Nrf2 to Cul3 for poly-ubiquitination [7,8]. Nrf2 can then accumulate in 
the nucleus, where it plays its role as a transcription factor by binding to DNA sequences called 
Antioxidant Response Elements (AREs) as a dimer with members of the small musculoaponeurotic 
Figure 1. Schematic simplified representation of thyroid hormone synthesis. Iodide (I−) enters thyroid
follicular cells by active transport via the sodium (Na+)-iodide symporter (NIS), and is then exported
via other channels into the follicular lumen (the colloid area), where it is oxidized to iodine (I) and
used in the iodination of thyroglobulin (Tg). Coupling between di- and/or mono-iodinated tyrosines of
Tg produces the thyroid hormones T4 and T3, attached to the Tg backbone. Tg is then endocytosed
into the thyroid follicular cells, where it is degraded inside lysosomes, ultimately releasing T4 and
T3 into the blood circulation via a monocarboxylate transporter (MCT). Steps affected by Keap1/Nrf2
signaling are highlighted in red font. They include: (i) a positive effect on the transcription of the gene
encoding Tg; (ii) a positive effect on the transcription of antioxidant and selenoprotein genes such as
Nqo1 (NAD(P)H quinone dehydrogenase 1), Gpx2 (glutathione peroxidase 2), and Txnrd1 (thioredoxin
reductase 1); (iii) a negative effect on Tg iodination; (iv) a positive effect on Tg proteolysis.
Under normal conditions, Keap1 acts as an adaptor that targets Nrf2 for poly-ubiquitination by
Cullin 3-based ubiquitin E3 ligase (Cul3) and subsequent degradation by the proteasome. The thiol
groups on specific Keap1 cysteines react readily with oxidants, including H2O2, and their oxidation
impairs the presentation of Nrf2 to Cul3 for poly-ubiquitination [7,8]. Nrf2 can then accumulate
in the nucleus, where it plays its role as a transcription factor by binding to DNA sequences called
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Antioxidant Response Elements (AREs) as a dimer with members of the small musculoaponeurotic
fibrosarcoma (Maf) family of proteins [9,10]. In this manner, activated Nrf2 induces the transcription of
a large battery of genes encoding antioxidant enzymes and various other cell-protective molecules [6].
Animal models have firmly established the importance of Keap1/Nrf2 signaling as an antioxidant
response system. Nrf2 was found to be dispensable for mouse development and growth, meaning that
Nrf2 knockout (KO) adult mice are viable and fertile [11]. On the other hand, Keap1 KO mice die shortly
after birth [12], precluding their use for physiological studies; however mice expressing lower levels
of Keap1, referred to as Keap1 hypomorphic or Keap1 knockdown (Keap1KD) mice, are viable and
fertile [13]. Research using the aforementioned mouse models, along with respective cellular Nrf2 gain-
and loss-of-function models, has elucidated many roles of Keap1/Nrf2 signaling in pathophysiology,
and has highlighted the Keap1/Nrf2 pathway as a plausible therapeutic target for a wide spectrum
of OS-related diseases affecting various tissues [14]. As mentioned, the thyroid, and specifically the
follicular cells which continuously produce and are exposed to H2O2, need to be able to adapt and
protect themselves against OS. However, information about the Keap1/Nrf2 pathway in the physiology
and pathophysiology of the thyroid has emerged only in the last few years, as summarized in our
previous review [5]. As new knowledge in this area has become available over the last two years,
we provide here an update on the topic of Keap1/Nrf2 signaling in the thyroid, focusing on the latest
studies by our group and others.
As mentioned, normal production of T4 and T3 by the thyroid is essential for homeostasis because
they act throughout the body to control development, growth, and metabolism [15–17]. As all tissues
depend on thyroid hormones for normal functioning, thyroid dysfunction with hormonal over- or
underproduction can be a cause of multiple symptoms and clinical signs. Thyroid diseases are
actually common in the population, and the most frequent ones are (i) hypothyroidism, which refers to
hypofunction of the gland, with thyroid hormone underproduction [18]; (ii) thyrotoxicosis, which refers
to increased levels of thyroid hormones due to either true overproduction (hyperthyroidism) or
increased liberation due to inflammation and destruction of the follicles [19,20]; (iii) autoimmune
thyroid disease, which is most often associated with hypothyroidism (Hashimoto’s thyroiditis, HT) but
in other cases with hyperthyroidism (Graves’ disease, GD) [21]; (iv) thyroid enlargement (also termed
goiter), either in a diffuse form, as is the case in GD and occasionally also in HT, or in the form of single
or multiple thyroid nodules (tumors); the latter are usually benign, even though thyroid carcinomas
are not very rare either [22,23]. Recent studies have highlighted links between the Keap1/Nrf2 pathway
and thyroid physiology as well as various of the aforementioned pathologies; these links will be briefly
reviewed in the respective following sections.
2. Thyroid Physiology
Our group has shown that, similar to its function in other tissues, Nrf2 is a key antioxidant
player in the thyroid. In studies using Nrf2 KO mice, mice with tissue-restricted deletion of Nrf2
(using Pax8-Cre recombinase that is expressed primarily in the thyroid and the kidney), and thyroid
follicular cell lines with inactivated Nrf2 or Keap1 (using the CRISPR/Cas9 method), we showed that
Nrf2 activity correlated positively with the mRNA expression levels of antioxidant and/or selenoprotein
genes such as Nqo1 (NAD(P)H quinone dehydrogenase 1), Gpx2 (glutathione peroxidase 2), and Txnrd1
(thioredoxin reductase 1), as well as with the protein levels of Nqo1 and selenoprotein S (SelS) [2].
More recently, we confirmed this further by demonstrating increased mRNA expression levels of Nqo1,
Gpx2 and Txnrd1 as well as increased protein abundance of Nqo1 in the thyroids of Keap1KD mice [24].
We also showed that the antioxidant function of Nrf2 is triggered by exposure to supraphysiological
amounts of iodide, in order to protect thyroid follicular cells from OS [2]. Another group has also
shown that iodide excess activates Nrf2 in the thyroid of rats [25].
In addition to its antioxidant function in thyroid follicular cells, Nrf2 was also found to impact two
central aspects of thyroid hormone synthesis. On the one hand, it directly upregulates the transcription
of the gene encoding thyroglobulin (Tg, the precursor protein of thyroid hormones) via two AREs in
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its upstream enhancer, and thereby positively regulates the protein abundance of Tg in the thyroid [2].
Interestingly, one of these AREs harbors a rare single-nucleotide polymorphism (SNP) in humans;
using reporter gene assays in thyroid follicular cell lines, we showed that the minor allele of this SNP
abrogated the basal and inducible transcriptional activity of the enhancer, thus behaving as a complete
loss-of-function mutation [26]. Furthermore, by analyzing data from a genome-wide association study,
we found statistically significant associations between circulating Tg levels (Tg is also partly secreted
in the bloodstream) and common SNPs in the genes encoding Nrf2 (NFE2L2) and Keap1 (KEAP1),
including, notably, a known functional SNP in the promoter of NFE2L2 [26].
On the other hand, in studies in mice, we found that Nrf2 suppresses the iodination of Tg,
both under normal conditions and under excess iodide conditions [2]. Specifically, Nrf2 KO mice
showed higher levels of iodinated Tg under normal conditions [2]. Exposure to excess iodide
normally suppresses Tg iodination to prevent excess thyroid hormone synthesis that could lead to
hyperthyroidism; this phenomenon is part of the mechanisms underlying the so-called autoregulation
of the thyroid gland [27]. Notably, in response to iodide overload, Nrf2 KO mice showed even higher
levels of iodinated Tg [2], suggesting that Nrf2 has a role in thyroid autoregulation. Although the precise
mechanisms underlying this effect have not yet been elucidated, we found that treatment of thyroid
follicular cell lines with 2-iodohexadecanal, an iodolipid considered to be one of the main mediators of
thyroid autoregulation [28], activated Nrf2, similar to iodide treatment [2]. Recently, we analyzed the
transcriptomic response of the mouse thyroid to iodide overload using next-generation RNA sequencing
in WT and Nrf2 KO mice. The results confirmed that iodide overload induces the Nrf2 cytoprotective
response. The results also showed that iodide upregulates inflammatory, immune, and fibrosis
pathways, and that these responses are exacerbated in the absence of Nrf2 [29]. The phenotypes of
Nrf2 KO and Keap1KD mice are summarized in Figure 2.
Antioxidants 2020, 9, x FOR PEER REVIEW 4 of 14 
of this SNP abrogated the basal and indu ible transcriptional activity of the enhancer, thus behaving 
s a complete loss-of-fu ction mut tion [26]. Furthermore, by an lyzing data from a genome-wid  
association study, we found statistically significant associations betwe  circulating Tg levels (Tg is 
also partly secreted in the bloodstream) and common SNPs in the gen s ncoding Nrf2 (NFE2L2) an  
Keap1 (KEAP1), including, notably, a known functional SNP in the promoter of NFE2L2 [26]. 
O  the ther hand, in st dies i  mice, we found that Nrf2 suppresses the iodination of Tg, both 
under ormal conditions and nder excess iodide co itions [2]. Specifically, Nrf2 KO mice showed 
hig er levels of iodinated Tg under no mal condit ons [2]. Exposure to excess iodide normally 
uppresses Tg iodination to prevent exc ss thyroid hormone synthesis that could lea  to 
hyperth roidism; this phe omenon is part of e mechanisms u derlying the so-called 
auto egulation of the t yr id gland [27]. Notably, in response to iodide overload, Nrf2 KO mice 
showed even higher levels of iodinated Tg [2], sugg sting that Nrf2 has a role in t yroid 
autoregulation. Although the precise mechanisms underlying this effect have not yet been elucidated, 
w  found that treatment of thyroid follicular cell lines with 2-i dohexadecanal, an iodolipi  
conside ed to b  one of the main m diators of thyroid autoregulati n [28], activated Nrf2, similar to 
iodide treatment [2]. Recently, we analyzed the transcriptomic r sponse of the mouse th roid to 
iodide overload using next-generation RNA sequencing in WT and Nrf2 KO mice. The results 
confirme  that iodide overload indu es the Nrf2 cyt protective response. The results also showed 
that iodide upregula es inflammatory, immune, and fibrosis pathways, and that thes  responses are 
exacerbated in the ab nce f Nrf2 [29]. The phe otypes of Nrf2 KO and Kea 1KD mice are 
summarize  in Figure 2. 
 
Figure 2. Schematic summary of the molecular, cellular, and/or clinical phenotypes observed in Nrf2 
KO mice and in Keap1KD mice (↑, increased; ↓, decreased). 
One difference between the thyroid and other tissues is that ROS are not primarily a byproduct 
of its physiology, but an indispensable part of it. As shown in Figure 1, thyroid follicular cells actively 
produce H2O2 to facilitate a cascade of redox reactions that sequentially oxidize iodide, iodinate 
tyrosine residues within Tg, and couple iodinated tyrosine residues of Tg to each other to form T4 
and T3. Interestingly, using cell lines (of non-thyroidal origin) and mouse embryonic fibroblasts 
expressing a series of Keap1 mutants, it was recently shown that four specific cysteines of Keap1 
(Cys226, Cys613, Cys622, and Cys624) are important for sensing H2O2 [30]. The same study also 
showed that there exists a fail-safe mechanism in which specific combinations of these cysteines can 
form a disulfide bond to sense H2O2. Moreover, this sensing mechanism appears to be distinct from 
that triggered by other Nrf2 inducers, such as electrophiles [30]. The implications of these recent 
findings for thyroid physiology are unknown, but the thyroid might serve as an interesting model to 
address their physiological relevance, since H2O2 is directly implicated in thyroid hormone synthesis. 
3. Overt Hypothyroidism and Thyroid Autoimmunity 
Figure 2. Schematic summary of the molecular, cellular, and/or clinical phenotypes observed in Nrf2
KO mice and in Keap1KD mice (↑, increased; ↓, decreased).
One difference between the thyroid and other tissues is that ROS are not primarily a byproduct of
its physiology, but an indispensable part of it. As shown in Figure 1, thyroid follicular cells actively
produce H2O2 to facilitate a cascade of redox reactions that sequentially oxidize iodide, iodinate tyrosine
residues within Tg, and couple iodinated tyrosine residues of Tg to each other to form T4 and T3.
Interestingly, using cell lines (of non-thyroidal origin) and mouse embryonic fibroblasts expressing a
series of Keap1 mutants, it was recently shown that four specific cysteines of Keap1 (Cys226, Cys613,
Cys622, and Cys624) are important for sensing H2O2 [30]. The same study also showed that there exists
a fail-safe mechanism in which specific combinations of these cysteines can form a disulfide bond to
sense H2O2. Moreover, this sensing mechanism appears to be distinct from that triggered by other Nrf2
inducers, such as electrophiles [30]. The implications of these recent findings for thyroid physiology are
unknown, but the thyroid might serve as an interesting model to address their physiological relevance,
since H2O2 is directly implicated in thyroid hormone synthesis.
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3. Overt Hypothyroidism and Thyroid Autoimmunity
Hypothyroidism occurs when the amount of thyroid hormones is not sufficient to match the
needs of the various tissues. Its clinical manifestations may not always be clinically noticeable at
early stages; they range from asymptomatic to life-threatening, and some of the most common ones
include fatigue, lethargy, cold intolerance, weight gain, constipation, hoarse voice, and dry skin, but the
clinical presentation can be quite variable [18]. One of the common causes of hypothyroidism is HT,
an autoimmune disease that leads to lymphocytic infiltration and inflammation of the thyroid as
well as thyroid follicular cell apoptosis. Like most other autoimmune diseases, HT is a multifactorial
condition influenced by environmental and genetic factors. Among the latter, several SNPs have been
found to modulate the risk of developing HT; they tend to reside in genes that are thyroid-specific
and/or related to autoimmunity, inflammation, or cellular defense to stress [31].
Like iodine, selenium is another trace element with high concentration in the thyroid, and it is a
component of various proteins (selenoproteins) with antioxidant and anti-inflammatory functions in
various tissues, including the thyroid; interestingly, selenoprotein genes with homeostatic roles in the
thyroid include the Nrf2-regulated genes Gpx2 and Txnrd1 [2]. A functional SNP (rs28665122) in the
promoter of the gene encoding selenoprotein S (SELENOS) has been shown to increase the risk of HT,
at least in some ethnic populations [32], though not in others [33]. In the Portuguese population where
the SELENOS promoter SNP was originally found to increase the risk of HT [32], we recently found that
this risk was further modulated by the genotype of the three functional SNPs (rs35652124, rs6706649,
and rs6721961) in the promoter of NFE2L2 [34]. Specifically, increased HT risk was associated with the
combined presence of minor alleles of the functional SNPs of the SELENOS and NFE2L2 promoters,
whereas the presence of only major alleles of the NFE2L2 SNP abolished the risk associated with the
SELENOS SNP minor allele [34]. We further found that, in Nrf2 KO mice, the expression levels of
selenoprotein S in thyroid follicular cells were reduced; conversely, in thyroid follicular cell lines,
experimentally reducing the expression of selenoprotein S reduced the activity of Nrf2. These findings
indicate that the basis for the genetic interaction between NFE2L2 and SELENOS in modulating the
risk of HT might be related to a bidirectional positive feedback between the Nrf2 and selenoprotein
S pathways [34]. Of note, the HT patient population in this study had overt hypothyroidism that
required substitution with exogenous thyroid hormone [32,34].
4. Subclinical Hypothyroidism and Goiter
Beyond the most common forms of goiter mentioned above (i.e., diffuse goiter in GD and
nodular goiter), various less common causes of thyroid enlargement also exist. Among them is a rare
genetic disease termed familial nontoxic multinodular goiter (FNTMNG); as its name implies, it is
characterized by occurrence in families (genetically transmitted in an autosomal dominant or X-linked
mode), normal thyroid function, and presence of multiple nodules in the thyroid gland. One of the
genes associated with this rare disease is KEAP1. Two loss-of-function mutations in KEAP1 have
been described, each in a respective family with FNTMNG [35,36]. The first reported family was
thoroughly phenotyped, and cosegregation of the phenotype and the mutation was convincingly
demonstrated [35], whereas in the latter family only the proband was genotyped [36]. Therefore, in a
recent study we used Keap1KD mice to verify whether decreased Keap1 levels can cause goiter.
We found that Keap1KD mice showed a diffuse goiter that was already detectable in early adult life
and became more prominent and fully penetrant in later life [24]. Histomorphometric analysis of the
thyroids showed that the goiter was characterized by markedly dilated thyroid follicles, and especially
an increased size of the colloid compartment, while there were no thyroid nodules or hyperplasia.
In early adult life, Keap1KD mice showed decreased plasma levels of T4; these were normalized in
later life, apparently by increased plasma levels of thyroid-stimulating hormone (TSH), the pituitary
hormone that stimulates follicular thyroid cell growth and function. Nrf2 was activated in the thyroid
of Keap1KD mice, as evidenced by increased mRNA levels of its target genes Nqo1, Gpx2, and Txnrd1,
as well as increased protein abundance of Nqo1. These findings indicate that loss of Keap1 function
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in mice can indeed cause goiter, though not necessarily with a nodular appearance as in the case of
patients with FNTMNG. The precise mechanism accounting for the goiter phenotype and the elevated
TSH levels warrants further research. Expression profiling of thyroidal genes and proteins in Keap1KD
mice showed changes in the abundance of the mature protein forms of several Tg-processing and
Tg-degrading cathepsin enzymes; this suggests that the pathogenesis of goiter in Keap1KD mice might
involve increased solubilization and lysosomal degradation of Tg [24]. The phenotypes of Keap1KD
mice are summarized in Figure 2.
The findings from Keap1KD mice suggest that chronic genetic activation of Nrf2 signaling may
have negative consequences for the thyroid gland [24]. However, analysis of data from a clinical
trial has shown that consumption of a broccoli sprout beverage (yielding pharmacologically active
amounts of the Nrf2-activating compound sulforaphane) is safe for thyroid hormonal, and autoimmune
status during a 12-week administration period [37]. Nevertheless, it appears prudent to monitor
thyroid function and thyroid volume (at least by palpation) in patients treated with Nrf2-modulating
compounds in clinical trials or clinical practice. In support of this concept, a recent case report
described a patient with multiple sclerosis (MS) who received treatment with the approved Nrf2
activator dimethyl fumarate (DMF). The patient had concomitant HT, which showed exacerbation after
2 months on DMF, leading to treatment discontinuation. The authors postulated that HT exacerbation
may be linked to the antioxidant effects of DMF, and they recommended monitoring of thyroid function
tests of MS patients treated with DMF, especially when they are affected by concomitant autoimmune
thyroid diseases [38].
5. Metabolism
Elevated TSH levels with normal T4 levels, as observed in Keap1KD mice [24], are indicative of a
mild form of hypothyroidism, called subclinical hypothyroidism. In this condition, increased secretion
of TSH by the pituitary provides additional stimulation to the thyroid that compensates for a mildly
deficient hormonogenetic capacity of the gland, thus managing to maintain T4 levels within the normal
range [39]. The apparent presence of subclinical hypothyroidism in Keap1KD mice [24] may have
practical relevance beyond our understanding of thyroid economy, and specifically in the broader
field of metabolic research. In addition to its antioxidant and cell-protective functions, the Nrf2
pathway has been implicated in metabolic regulation, either in peripheral tissues or via interactions
with central signaling systems that respond to nutritional inputs [40]. In that context, Keap1KD mice,
as a model of constitutive Nrf2 pathway activation, have been shown to be protected against metabolic
disease (obesity, insulin resistance, type 1 and type 2 diabetes). This effect has been attributed not
only to the classic protective effects of Nrf2 against oxidative stress damage in the hypothalamus [41]
and in β cells [42,43], but also to novel roles of Nrf2 in the repression of gluconeogenic [44,45] and
lipogenic [37] pathways. Of note, none of these metabolic studies assessed the thyroidal status of the
respective animals. As it is practically impossible to precisely predict if and how an experimental
diet (e.g., high-fat, high-sucrose, etc.) or a disease-related genetic background (e.g., lipodystrophy,
db/db, etc.) may affect the timing and severity of thyroid dysfunction specifically in Keap1KD mice,
we suggest that metabolic studies using these animals should routinely evaluate thyroidal status in all
experimental groups. Conversely, only two studies have evaluated energy expenditure in Keap1KD
mice, one using 4-month-old male mice on a high-fat diet for 2 months [45], and the other using
3-month-old male mice in a lipodystrophy background [37]. In these studies, hypomorphism for Keap1
did not significantly alter energy expenditure in the context of the respective disease model, but neither
study directly compared Keap1KD mice to WT controls without other genetic or pharmacological
interventions [37,45]. Thus, the possible metabolic correlates of subclinical hypothyroidism in Keap1KD
mice warrant further investigation, and such studies might help to address the existing controversy
regarding the effects of moderate, subclinical thyroid dysfunction on energy expenditure [46].
Lastly, an interesting observation came from a study in mice that found that administration of
a high-fat diet decreased the nuclear levels and increased the cytoplasmic levels of Nrf2 in thyroid
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follicular cells, indicating a suppression of Nrf2 activity. This effect could be abrogated by various
interventions, including a low-fat diet, caloric restriction, exercise, or treatment with the Nrf2 activator
quercetin. The expression levels of microRNA miR-200a in the thyroid of high-fat diet-treated mice
were increased [47], which might have a causal effect on the activity of Nrf2, given that miR-200a has
been previously shown to target Keap1 [48].
6. Hyperthyroidism/Thyrotoxicosis and Graves’ Orbitopathy
In contrast to hypothyroidism, hyperthyroidism and thyrotoxicosis are characterized by excessive
production and/or liberation of thyroid hormones. Like hypothyroidism, hyperthyroidism is more
common in women; the most common cause in younger patients is autoimmune thyroid disease
(specifically GD), whereas in older patients it is hyperfunctioning thyroid nodules, either single (toxic
adenoma) or multiple (toxic multinodular goiter) [19]. Regardless of the cause, the high concentrations
of circulating thyroid hormones result in overstimulation of peripheral tissues, inducing an overall
increase in metabolism and an increased demand for energy and oxygen. Therefore, it is no surprise
that hyperthyroidism/thyrotoxicosis has also been associated with OS and with activation of Nrf2
signaling in the target tissues of thyroid hormones. Specifically, it has been known for several years
that thyroid hormone administration induces activation of Nrf2 in the rat liver, and that this activation
is suppressed by pretreatment with the ROS scavenger N-acetyl cysteine [49]. In the same line,
it was recently shown that in the lymphoid tissues of mice treated with high doses of exogenous T4,
thyrotoxicosis induces an increase in ROS levels, activates Nrf2, and upregulates the transcription
of genes encoding antioxidant enzymes [50]. Activation of Nrf2 by thyroid hormone was further
confirmed in other recent studies focusing on the heart [51] and the liver [52].
Some studies have found that natural antioxidants, such as curcumin and vitamin E, can decrease
OS in the peripheral tissues of animals with T4-induced experimental thyrotoxicosis [53], and can
prevent the marked activation of the antioxidant response [54]. A recent study assessing these
effects in the rat heart employed in vitro modelling to suggest that they may involve modulation of
Keap1/Nrf2 signaling by curcumin and vitamin E [55]. In another recent study, quercetin, a flavonoid
with antioxidant properties, was found to protect rats from thyrotoxicosis-induced liver damage [56].
As quercetin is a known Nrf2 activator, the study also employed Nrf2 KO rats and found that the
protective effects of quercetin against thyrotoxicosis-induced liver damage were diminished in these
animals, which suggests that they may be mediated by Nrf2 [56].
In GD, the autoimmune reaction does not target only the thyroid, causing hyperthyroidism,
but occasionally also the eye and its surrounding tissues (muscles and fat), causing Graves’ orbitopathy
(GO), a sight-threatening ocular disease [57]. While the pathogenesis of GO is not well understood, it is
known to involve strong components of OS, inflammation, and periorbital fat accumulation, as well
as to have a strong clinical correlation with smoking [58]. Treatment of mild forms mainly includes
smoking cessation and oral administration of the antioxidant selenium, whereas treatment of moderate
and severe forms is problematic and is based on corticosteroids and targeted immunomodulatory
agents [58]. Thus, GO, albeit rare, continues to represent an important unmet medical need. A recent
study using a mouse model of GO found that polydatin, a natural antioxidant, can activate Nrf2,
upregulate antioxidant genes, reduce the production of ROS, and inhibit adipose tissue expansion
and lipid droplet accumulation in vivo [59]. In addition, in orbital fibroblasts cultured in vitro,
silencing Nrf2 reduced the protective effects of polydatin against H2O2-induced OS [59]. This is the
first study to address the involvement of Nrf2 and its modulators in GO, and it is hoped that further
research in this field can yield new approaches to combat this potentially sight-threatening disease.
We have recently reviewed the effects that various natural compounds, including Nrf2 activators,
can have on the thyroid gland to favor or suppress thyroid hormone production, with potential utility
against hypothyroidism or hyperthyroidism, respectively [60]. The aforementioned recent studies
further show that such compounds may also have utility in counteracting the manifestations of thyroid
dysfunction in peripheral tissues.
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7. Thyroid Carcinomas
Most thyroid carcinomas are generally associated with a better prognosis compared to other
types of cancer, yet the disease and its treatment are often associated with substantial morbidity as
well as a negative impact on the patient’s quality of life. The favorable prognosis applies especially
to differentiated thyroid carcinoma (DTC), which is the most frequent type, and originates from
thyroid follicular cells, whereas other types like poorly differentiated thyroid carcinoma (PDTC,
likely representing an evolution of DTC) and medullary thyroid carcinoma (MTC, originating from
calcitonin-secreting parafollicular cells that reside between the thyroid follicles) have a poorer prognosis,
and anaplastic thyroid carcinoma (ATC) is almost always lethal (recently reviewed in [61]). The most
common type of thyroid cancer is papillary thyroid carcinoma (PTC), which is a form of DTC [23].
Activation of Nrf2 is generally known to play a dual role in cancer, on the one hand protecting
normal cells against oxidative damage and thereby preventing carcinogenesis, while on the other hand
conferring a survival advantage to established cancer cells [62]. In our previous review on the roles
of Nrf2 in the thyroid, we have thoroughly reviewed the studies examining its implication in PTC
and other types of thyroid cancer [5]. In summary, we had initially observed that Nrf2 is commonly
activated in PTC, where it regulates the antioxidant defense and promotes the survival of cancer
cells [63]. This observation was subsequently confirmed by other groups [64], and the underlying
molecular mechanisms began to be unraveled; these include somatic mutations in KEAP1 [65],
epigenetic hypermethylation of KEAP1 or other genes in the Nrf2 pathway [64], etc. In the present
work, we review a few recent studies that have shed further light into the involvement of Nrf2 in
thyroid cancer.
Transcriptomic profiling of PTC samples compared to adjacent normal thyroid tissues identified the
Nrf2-mediated oxidative stress response as one of six commonly upregulated oncogenic pathways [66].
Somatic mutations in KEAP1, NFE2L2, or other Nrf2 pathway components were not reported in this
study, which is not surprising, knowing that the frequency of such mutations in thyroid cancer is
lower than in other cancer types with activated Nrf2 signaling [64,65], and given the small sample
size of the specific study [66]. Another study found higher Nrf2 mRNA levels and Nrf2 protein
abundance in PTC samples compared to normal tissues [67]; of note, Nrf2 is known to induce the
transcription of its own gene (at least in the mouse), via an ARE element in the gene promoter [68].
Further, the same study showed that inhibition of microRNA miR-17-5p in a PTC cell line decreased
Nrf2 mRNA expression levels [67]. Another study found increased expression of the long non-coding
RNA lung cancer associated transcript 1 (LUCAT1) in PTC, as well as a positive correlation between
LUCAT1 expression levels and unfavorable clinicopathological parameters [69]. In two PTC cell lines,
knockdown of LUCAT1 decreased Nrf2 mRNA expression levels and Nrf2 protein abundance, while at
the same time it reduced cell proliferation and invasion, and induced cell-cycle arrest and apoptosis [69].
Lastly, another study showed that Pinelliae rhizome (PR), a component of a traditional medicine
decoction, decreased the protein abundance of Nrf2 in the nucleus of PTC cell lines in a dose-dependent
manner, and decreased their viability [70]. Knockdown of Nrf2 via small interfering RNA (siRNA) in
the PTC cell lines decreased their viability and had an additive or synergistic effect with PR. In mice
orthotopically transplanted with a PTC cell line, the combination of Nrf2 knockdown in the PTC cells
before transplantation and PR treatment of the animals significantly decreased the tumor burden
and extended the survival of the animals. In contrast, when the PTC cells were transplanted into the
thyroids of Nrf2 KO mice, the tumor burden was increased, survival was shortened, and the protective
effect of PR treatment was lost [70]. Taken together, the findings of the aforementioned recent studies
further support the original concept that the Nrf2 pathway is activated in PTC and has a protective
effect in thyroid carcinoma cells [63].
Preclinical data have suggested that dipeptidyl peptidase-4 (DPP-4) inhibitors, a glucose-lowering
treatment for diabetes, may promote metastatic progression of preexisting cancer via activation of Nrf2 in
the cancer cells [71]. However, a subsequent population-based clinical study from Germany did not find
an association between DPP-4 inhibitor treatment and cancer metastasis [72]. Recently, another clinical
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study from Korea tested for associations between glucose-lowering drugs and cancer metastasis in
several cancer types; no associations were found, except for a weakly significant association between
DPP-4 treatment and thyroid cancer metastasis (hazard ratio 3.89, confidence interval 1.04–9.64) [73].
The authors acknowledged that this finding should be taken with caution, because the number of
patients with thyroid cancer in the study was small, and the frequency of thyroid cancer metastasis
was low in all patient groups [73]; it might thus represent a spurious association, and further studies
are required to confirm or refute it.
8. Concluding Remarks
The Keap1/Nrf2 system is known to play important roles in redox balance and metabolic
homeostasis, with documented beneficial effects in models of inflammation, autoimmunity, metabolic,
and neurodegenerative diseases, and many other chronic conditions [14]. The present focused review
of the thyroid field suggests that the Keap1/Nrf2 system might also have utility in the search for
biomarkers and/or drug targets for thyroid pathologies. In view of the current state of knowledge as
outlined above, in our opinion, some of the main areas for future research around Nrf2 and thyroid are
the following: (i) further elucidation of the mechanisms by which Nrf2 signaling impacts the thyroid
hormone synthesis and secretion apparatus; (ii) documentation of Nrf2 activity status in models
of hyperthyroidism/thyrotoxicosis, hypothyroidism, and goiter; (iii) in vivo characterization of the
effects of Nrf2-activating antioxidant substances on the thyroid; (iv) investigation of the potential
utility of Nrf2 modulation in the context of thyroid autoimmunity; and (v) elucidation of the potential
role of altered thyroid function in the various models studying the implication of Nrf2 in metabolic
disease. Our ongoing research program aims to address specifically the aforementioned knowledge
gaps, with the ultimate goal of devising new strategies to improve the prevention and treatment of
thyroid diseases.
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